MedTrace Logo

P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens

NCT02533323 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-05-09

No results posted yet for this study

Summary

This prospective study was conducted to evaluate the efficacy and safety profiles of first-line combined gemcitabine, oxaliplatin, and Pegaspargase (P-Gemox) in newly diagnosed, nasal type, extranodal natural killer/T-cell lymphoma.

Conditions

  • Lymphoma, Extranodal NK-T-Cell

Interventions

DRUG

gemcitabine

gemcitabine :1250mg/m2 (ivdrip) on days 1

DRUG

oxaliplatin

oxaliplatin :85 mg/m2 (ivdrip) on day 1

DRUG

pegaspargase

pegaspargase : 2500 IU/m2 (intramuscular injection)

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • yue lu, MD. · Department of Hematological Oncology, Sun Yat-sen University Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2016-09-30
Completion
2017-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02533323 on ClinicalTrials.gov